Nuzyra's cost varies based on insurance coverage, pharmacy, and dosage [1]. A 30-day supply of Nuzyra (400mg) can range from approximately $5,000 to over $6,000 [1].
How much does Nuzyra cost with insurance?
Insurance coverage significantly impacts the out-of-pocket cost of Nuzyra. Many insurance plans may offer coverage, but the specific copay or coinsurance will depend on your plan's formulary and deductible [1]. Patients may be eligible for manufacturer-supported savings programs, which can help reduce these costs [2].
Are there patient assistance programs for Nuzyra?
Yes, patient assistance programs are available for Nuzyra. For example, the Nuzyra Savings Program offers eligible commercially insured patients a savings card that can reduce their out-of-pocket costs to as low as $0 per prescription, subject to program terms and conditions [2]. Eligibility requirements typically apply to these programs.
What are the different strengths and forms of Nuzyra, and how does that affect cost?
Nuzyra is available in two forms: an oral tablet and an intravenous (IV) infusion [3]. The oral dosage strength is typically 400 mg [1]. The cost can differ between the oral and IV formulations, with IV administration potentially involving additional costs for the drug itself and the associated infusion services [1].
When does Nuzyra's patent protection expire?
The patent protection for Nuzyra, also known by its generic name omadacycline, is a key factor influencing its market exclusivity and the potential for generic competition [4]. Information regarding specific patent expiry dates and any associated litigation can be found through resources that track drug patents [4].
Who are Nuzyra's main competitors?
Nuzyra is an antibiotic used to treat bacterial pneumonia and skin infections [3]. Its competitors include other antibiotics that target similar pathogens and indications. The competitive landscape is dynamic, with new agents and generic alternatives continuously emerging [4].
What is the mechanism of action for Nuzyra?
Nuzyra is a tetracycline-class antibacterial, specifically a novel oral and intravenous (IV) tetracycline [3]. It works by inhibiting bacterial protein synthesis, which is essential for bacterial growth and survival [3]. This mechanism targets ribosomal functions within bacteria.
What clinical trials have been conducted for Nuzyra?
Clinical trials have demonstrated Nuzyra's efficacy in treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) [3]. These trials compare Nuzyra to existing standard-of-care treatments to establish its safety and effectiveness profile.
Sources:
[1] https://www.goodrx.com/nuzyra
[2] https://www.nuzyra.com/savings-and-support/
[3] https://www.nuzyra.com/
[4] https://drugpatentwatch.com/